Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors

Journal of Medicinal Chemistry

Volumn 44, Issue 2, 2001, Pages 155-169

  Schaal, W ^a   Karlsson, A ^a   Ahlsen G ^a   Lindberg, J ^a   Andersson, H O ^a   Danielson, U H ^a   Classon, B ^b   Unge, T ^a   Samuelsson, B ^c   Hulten J ^a   Hallberg, A ^a   Karlen A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; SULFANILAMIDE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BINDING; DRUG CONFORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION;

CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0035905831     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm001024j     Document Type: Article

References (40)

1. Active human immunodeficiency virus protease is required for viral infectivity
2. Protease inhibitors: Current status and future prospects
3. The year in review: Antiretroviral treatment
4. Mutations in retroviral genes associated with drug resistance
5. Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding affinities
6. Cyclic HIV protease inhibitors: Synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas
7. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor
8. Inhibitors of the C2-symmetric HIV-1 protease. Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2′ side chains
9. Structure-based inhibitors of HIV-1 protease
10. Cyclic HIV protease inhibitors: Design and synthesis of orally bioavailable, pyrazole P2/P2′ cyclic ureas with improved potency
11. Nonsymmetric P2/P2′ cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues
12. Comparative quantitative structure-activity relationship studies on anti-HIV drugs
13. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild-type and protease inhibitor resistant mutants of HIV
14. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy
15. Design and fast synthesis of C-terminal duplicated potent C2-symmetric P1/P1′-modified HIV-1 protease inhibitors
16. Synthesis of new heterocycles: Part XV - Synthesis of novel cyclic & acyclic sulphamides
17. Heterocycles containing the sulfamide moiety
18. The mitsunobu reaction
19. 2,4-Dinitrobenzenesulfonamides: A simple and practical method for the preparation of a variety of secondary amines and diamines
20. Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995-1998
21. Palladium-catalyzed cross-coupling reactions of organoboron compounds
22. Dielectric parameters relevant to microwave dielectric heating
23. Microwave promoted palladium-catalyzed coupling reactions
24. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs
25. AMBER* torsional parameters for the peptide backbone
26. Semianalytical treatment of solvation for molecular mechanics and dynamics
27. MacroModel - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics
28. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins
29. Validation of QSAR's
30. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA
31. AM1: A new general purpose quantum mechanical molecular model
32. Calculated and experimental low-energy conformations of cyclic urea HIV protease inhibitors
33. Stereoisomers of cyclic urea HIV-1 protease inhibitors: Synthesis and binding affinities
34. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules
35. 3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: Comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors
36. Comparative molecular field analysis (CoMFA) of a series of symmetrical. Bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors
37. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: Application of comparative molecular field analysis
38. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures